Abstract:Arteriosclerosis, Thrombosis, and Vascular Biology, Ahead of Print. Cardiovascular disease (CVD) remains a major health burden despite significant therapeutic advances accomplished over the last decades. It is widely and increasingly recognized that systemic inflammation not only represents a major cardiovascular risk and prognostic factor but also plays pivotal roles in CVD development and progression. Despite compelling preclinical evidence suggesting large potential of anti-inflammatory pharmacological interventions across numerous CVDs, clinical translation remains incomplete, mainly due to (1) yet undefined molecular signaling; (2) challenges of safety and efficacy profile of anti-inflammatory drugs; and (3) difficulties in identifying optimal patient candidates and responders to anti-inflammatory therapeutics, as well as optimal therapeutic windows. Randomized controlled trials demonstrated the safety/efficacy of canakinumab and colchicine in secondary cardiovascular prevention, providing confirmation for the involvement of a specific inflammatory pathway (NLRP3 [NACHT, LRR, and PYD domain-containing protein 3] inflammasome/IL [interleukin]-1β) in atherosclerotic CVD. Colchicine was recently approved by the US Food and Drug Administration for this indication. Diverse anti-inflammatory drugs targeting distinct inflammatory pathways are widely used for the management of other CVDs including myocarditis and pericarditis. Ongoing research efforts are directed to implementing anti-inflammatory therapeutics across a growing number of CVDs, through repurposing of available anti-inflammatory drugs and development of novel anti-inflammatory compounds, which are herein concisely discussed. This review also summarizes the main characteristics and findings of completed and upcoming randomized controlled trials directly targeting inflammation in CVDs and discusses the major challenges and future perspectives in the exciting and constantly expanding landscape of cardioimmunology.

Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies

Exploration of Molecular Pathogenesis and Therapeutic Strategies

Nanocarrier-Based Targeting of Cluster of Differentiation 44 for Treating Atherosclerosis: A Review

The endocannabinoid system in cardiovascular function: novel insights and clinical implications

Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases

The CB2 cannabinoid receptor as a therapeutic target in the central nervous system

Non-Psychoactive Phytocannabinoids Inhibit Inflammation-Related Changes of Human Coronary Artery Smooth Muscle and Endothelial Cells

Dissecting the role of cannabinoids in vascular health and disease

Endocannabinoids and Cannabinoid Receptors in Atherosclerosis

The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update

Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases

Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024)

Differential Regulation of MMPs, Apoptosis and Cell Proliferation by the Cannabinoid Receptors CB1 and CB2 in Vascular Smooth Muscle Cells and Cardiac Myocytes

Cannabinoid effects in the microvasculature - CB, or not CB? That is the question! A mini-review

Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products

Therapeutic potential of agents targeting cannabinoid type 2 receptors in organ fibrosis

The progress of small molecules against cannabinoid 2 receptor (CB2R)

The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease

Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease

Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential

Neuroprotection and Beyond: The Central Role of CB1 and CB2 Receptors in Stroke Recovery